Amgen Reports 56% Increase in Biosimilar Sales

August 05, 2021

Amgen reported a strong increase in biosimilar sales for the year but said competition is forcing down prices and affecting revenues for its originator products, too.

Ophthalmology Group Opposes Payer Recommendations for Bevacizumab Biosimilars
Celltrion Dominates Republic of Korea Drug Exports, Targets Latin America
Average Net Price for Insulin Glargine Declined After Basaglar Won FDA Approval
Not So Different: Should Biosimilar Variations Be Concerning?